An edition of Beyond The Blockbuster Drug (2005)

Beyond The Blockbuster Drug

Strategies for nichebuster drugs, targeted therapies and personalized medicine.

by

  • 0 Ratings
  • 0 Want to read
  • 0 Currently reading
  • 0 Have read
Cover of: Beyond The Blockbuster Drug by
Not in Library

My Reading Lists:

Create a new list

Check-In

×Close
Add an optional check-in date. Check-in dates are used to track yearly reading goals.
Today
Notes
  • 0 Ratings
  • 0 Want to read
  • 0 Currently reading
  • 0 Have read
Notes

Buy this book

Last edited by EdwardBot
November 10, 2011 | History
Edit
An edition of Beyond The Blockbuster Drug (2005)

Beyond The Blockbuster Drug

Strategies for nichebuster drugs, targeted therapies and personalized medicine.

by

  • 0 Ratings
  • 0 Want to read
  • 0 Currently reading
  • 0 Have read

The blockbuster model now delivers just 5% return on investment and only one in six new drug prospects will deliver returns above their cost of capital, as a result competitive pressures and falling R&D productivity will instigate a new pharmaceutical model that replaces the unsustainable blockbuster model; personalized medicine and the "nichebuster" (in this book, Gilbert Mertens coined the term “nichebuster”).
This report, Beyond the Blockbuster Drug: Strategies for nichebuster drugs, targeted therapies and personalized medicine, examines targeted therapies and targeted drug delivery strategies as alternative investment options for pharmaceutical companies, in the face of declining returns and slow growth in the blockbuster market. This report’s strategic insight is also supported by in-depth interviews with thought leaders from the pharmaceutical industry, providing you with their insight into how tomorrow’s pharmaceutical business model will develop. This report analyzes the niche pharmaceutical sectors with the greatest potential for profit and future growth. Harness the technological advances in personalized medicine and be part of the "nichebuster" revolution set to drive market growth and produce the market leading drugs of tomorrow.

Publish Date
Publisher
Reuters Business Insight, London
Language
English
Pages
120

Buy this book

Subjects
medicines, blockbuster drugs, pharma business model
People
Gilbert Mertens
Places
global
Times
2000-2020

Showing 1 featured edition. View all 1 editions?

Edition Availability
Cover of: Beyond The Blockbuster Drug
Beyond The Blockbuster Drug: Strategies for nichebuster drugs, targeted therapies and personalized medicine.
2005, Reuters Business Insight, London
Paperback in English
  • Not in Library

Add another edition?

Book Details

Table of Contents

Table of Contents
Beyond the blockbuster drug: Strategies for nichebuster drugs, targeted therapies and personalized medicine.
Acknowledgements 8
Executive summary 14
The blockbuster: An unsustainable model 14
Industry at a crossroads 15
Beyond the blockbuster: Personalized medicine 15
Targeted medicine: oncology 16
New drug technologies: discovery and delivery 17
Drug development: outsourcing and partnering 18
Case study: Roche 19
Case study: Novartis 20
Creating tomorrow�s winning company 21
Chapter 1 The blockbuster: An
unsustainable model 24
Summary 24
Introduction 25
The rise and fall of the blockbuster phenomenon 27
The blockbuster phenomenon 27
When blockbusters come off patent 29
Implications for the future of the industry 31
Chapter 2 The industry at a crossroads 34
Summary 34
The Failure of R&D 34
The R&D performance gap 38
The failure of the "mega-merger" 41
Conclusion 44
Chapter 3 Beyond the blockbuster:
Personalized medicine 48
Summary 48
Where next? 49
Personalized medicine 51
Gene-based therapies reach the market by 2010 51
The race for new therapies 53
Conclusion 55
Chapter 4 Targeted medicine: Oncology 58
Summary 58
Introduction 59
A promising therapeutic field 61
Gleevec 61
Therapeutic focus on cancer 62
Drug discovery deals 63
Molecularly targeted therapies 66
Herceptin 67
Promising treatments for breast cancer 69
Advances in treatment for colorectal cancer 70
Prostate cancer 70
Conclusion 71
Chapter 5 Targeted drug delivery 76
Summary 76
New drug technologies 78
Customized medicine 79
A future of unseen opportunity 80
Advances in science 81
Targeted drug delivery 82
Oral delivery of macromolecules 83
Enhanced bioavailability / Efflux inhibitors 83
SCF technologies 84
Inhibiting P-gp action 84
Injectable, biodegradable depot drug delivery 85
Parenteral drug delivery 85
PEGylation to deliver protein and cancer drugs 86
Conclusion 87
Chapter 6 Drug development: Outsourcing
and partnering 90
Summary 90
Introduction 91
Why outsource? 91
The changing CRO model 92
Biotechs are reshaping drug development 93
Moving from vendor to strategic partner 93
Realizing strategic value 94
The ideal CRO model for the new outsourcing paradigm 96
Models for outsourcing 97
Do-it-yourself 97
Architect 97
Integrated design and build 98
Risk-sharing 98
Conclusion 99
Chapter 7 Case study: Roche 102
Summary 102
Banking on "nichebusters" 102
A radically transformed Roche portfolio 103
Diagnostics: An essential precursor for targeted medicines 104
R&D partnerships for faster growth 106
Conclusion 107
Chapter 8 Case study: Novartis 110
Summary 110
Targeted medicine 110
Breadth vs depth? 111
Novartis portfolio 112
PTK787 (ZX 222584) 112
ICL670 113
Gimatecan 113
Femara 114
Conclusion 115
Beyond targeted medicine 115
Chapter 9 Creating tomorrow�s winning
company 120
Summary 120
Prisoners of ROI 121
Adding a dimension to the matrix 121
Pharmaceutical companies as service providers 122
Boom times knocking at the door.. 123
� But not without change 124
Alliances fuel innovation 125
Growing a product to its maximum sales 126
Medicines for "My" body 127
A broader view of the competition 128
Far-reaching psychological and structural transformation 129
Conclusion 131
Index 132
Figures
Figure 1.1: From therapy to health maintenance busters 26
Figure 2.2: Emergence of an elite group of R&D spenders 35
Figure 2.3: Ten year evolution of a drug�s development cost 36
Figure 2.4: Declining R&D success* 37
Figure 2.5: Drug candidates of major R&D-driven pharma companies 38
Figure 2.6: Performance gap in R&D 39
Figure 2.7: Breakdown of projects by clinical phase and source of drug 40
Figure 2.8: No economies of scale in pharmaceutical R&D 42
Figure 2.9: Shareholder returns of merged and non-merged companies 44
Figure 2.10: The need for alliances and partnering 45
Figure 3.11: Genomic research based products reach the market before 2010 52
Figure 3.12: Genetically manufactured substances in the pipeline 53
Figure 4.13: Therapeutic focus of clinical pipeline activity 62
Figure 4.14: Global oncology players, 2002 63
Figure 4.15: Deals by therapeutic focus (Sept �02 t0 Mar �04) 64
Figure 4.16: Therapeutic focus by company (Sept �02 to Mar �04) 65
Figure 4.17: Development of the global oncology market 2001-2008* 66
Figure 4.18: Breast cancer market opportunities 69
Figure 6.19: Today�s R&D environment 92
Figure 6.20: The future R&D environment 96
Figure 7.21: Leading products in the Roche portfolio, 2003 103
Figure 7.22: The Roche business model: Innovation and diagnostics 104
Table 8.23: Novartis, sales by type of business activity ($m), 2003 111
Figure 8.24: External sources contribute to Novartis� product growth 115
Figure 9.25: Drug discovery holds immense possibilities 126
Figure 9.26: Reshaping the "traditional" healthcare model 128
Figure 9.27: The integrated virtual MegaPharma-Biotech company 130
List of Tables
Table 3.1: Drug candidates in early stage clinical development, 2002-2003 54
Table 4.2: Cancer pathologies (selected) in the US 60
Table 5.3: Novel drug technologies 78
Table 7.4: Roche: Early stage development alliances 107
Table 8.5: Estimated product launch timetable for Novartis� drug pipeline 114

Edition Notes

Published in
London

Contributors

Contributor
Dr. Hatsuo Aoki, President & Ceo, Fujisawa Pharmaceutical Co. Ltd.
Contributor
Dr. Anand Burman, President & Ceo, Dabur Oncology Ltd.
Contributor
Barry Clare, Director, Clarat Ltd.
Contributor
Dr. Guenter Festel, President, Festel Capital
Contributor
Dr. Spiros Fotinos, Managing Director, Lavipharm Laboratories Inc
Contributor
Dr. Tugrul T. Kararli, General Manager, Pharma Circle LLC.

The Physical Object

Format
Paperback
Number of pages
120

ID Numbers

Open Library
OL24456540M

Work Description

See the description "about the book".

In this book, Gilbert Mertens, a renowed strategic thinker, coined the term "nichebusters". In 2000, he already came up with facts and figures about the declining blockbuster sales of medicines (those medicines that reach sales of at least US $ 1 billion) and the need for the pharmaceutical industry to adapt to reality, to change its business model...it took the industry ten years to follow his advise

Community Reviews (0)

Feedback?
No community reviews have been submitted for this work.

Lists

This work does not appear on any lists.

History

Download catalog record: RDF / JSON
November 10, 2011 Edited by EdwardBot resolve author redirects
February 18, 2011 Edited by Ilse Andiel, MD completed the information
February 18, 2011 Edited by Ilse Andiel, MD You asked for a description...but the book has been described already, so, my friends, I refer to the existing description.
November 23, 2010 Edited by Serge Gailly Added new cover
November 22, 2010 Created by Ilse Andiel, MD Added new book.